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Background
Acute myocardial infarction (MI) remains a leading cause
of patient death and morbidity. Prognosis following MI
has been shown to be strongly associated with small
changes in left ventricular remodeling. Omega-3 fatty
acid (PUFAs) supplementation may have a number of
beneficial pleiotropic effects, including enhancement of
myocardial relaxation1 and reduction of vascular tone.2
One prospective, randomized trial demonstrated signifi-
cant survival benefit for PUFAs following acute MI.3
However, the mechanism and potential myocardial
changes during the convalescent phase post MI from
PUFAs have not been well described.
Methods
The OMEGA-REMODEL study was a randomized, dou-
ble-blinded, placebo controlled trial of PUFA supplemen-
tation post acute MI. A total of 358 patients were
randomized to study therapy with PUFAs (n=180) or
matching placebo (n=178) and underwent baseline
assessment by CMR 4-28 days following MI, with follow-
up after 6 months of randomized therapy. The primary
endpoint was changes in left ventricular end-systolic
volume indexed to body surface area (LVESVI). Second-
ary outcomes included a) change in total infarct size,
b) expansion of MECVF within noninfarcted myocar-
dium, and c) changes in systemic biomarkers.
Results
Baseline demographics for the entire cohort and both
treatment arms are shown in Table 1. CMR characteris-
tics, PUFAs levels, and biomarkers for baseline and
6-month post-treatment values of each treatment arm
are shown in Table 2 and Figure 1. There were no sig-
nificant differences for any ventricular parameters,
infarct size or MECVF at baseline. After 6 months of
therapy, follow-up CMR revealed a significant difference
for percent change of LVESVI (-5.4±16.6 PUFAs versus
0.75±21.0 Placebo, p=0.01) and MECVF (-1.3±14.9
PUFAs versus 3.8±18.0 Placebo, p=<0.05) between the
treatment arms. In addition, the inflammatory biomar-
kers, hsCRP and myeloperoxidase, were substantially
reduced in the PUFAs treated arm as compared with
the placebo arm (-98.2±243.6% versus -30.5±221.5%
p<0.01, and -0.8±6.7 versus +0.8±5.3 p=<0.05, respec-
tively). Finally, the percent reduction in ST2 after
6 months, a biomarker of myocardial fibrosis, was signif-
icantly greater in the PUFAs treated arm (-1.35±8.0 ver-
sus +0.92±7.5, p=0.03). Adjusted multivariable analysis
demonstrated an independent association for change in
PUFAs levels with adverse LV remodeling.
Conclusions
The results of this study demonstrated a significant
reduction in LVESVI and MECVF for patients treated
with high-dose PUFAs as compared to placebo. Further
assessment of systemic biomarkers demonstrated a sub-
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Figure 1 Baseline demographics
Figure 2 Baseline and 6-month post treatment results
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fibrosis for the PUFAs treated arm. These findings
represent the first description of the effect of PUFAs on
myocardial tissue phenotypes during the convalescent
phase post MI and may suggest potentially important
pathophysiological pathways for their pleiotropic effects.
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